Amplicon Bricks
Creating Value from DNA
We are a biotech startup focused on Creating Value from DNA. Through the development of innovative, accessible solutions based on a proprietary plasmid DNA platform, we create products for the prevention, diagnosis and treatment of human, animal, and plant diseases.
Our Philosophy
Founded on November 1, 2023, we are in Dina Huapi, Río Negro Province – Argentina. We work inspired by the stunning scenario of Patagonia, surrounded by pristine rivers, lakes and the breathtaking beauty of the Andes Mountains.
At Amplicon Bricks, cutting-edge science & innovation goes hand in hand with an unwavering commitment to ethical practices and strong family values. Our research processes are guided by rigorous standards that emphasize respect for life and natural integrity. More than a laboratory or a product line, we’re building a community —inside our walls and out in the world. We understand that balancing professional breakthroughs with family responsibilities is crucial. When personal fulfillment and professional purpose converge, the entire community—from our team to the breakthroughs we deliver—thrives.
​
Our Purpose and Values
​
Amplicon Bricks was born with a mission: to put science at the service of the common good, bridging innovation and social well-being. Our purpose is to improve lives through innovations that facilitate the diagnosis, prevention, and treatment of human, animal, and plant diseases, fostering a healthier and more sustainable future.
​
The VALUES that drive us are:
-
​Respect for life: we are driven to develop scientific solutions that promote human well-being and dignity at all stages of human life.
-
Accessibility: we design cost-efficient solutions with low complexity of application to promote access to health.
-
Quality: we are committed to developing high quality products for the benefit of human, animal and plant health.
-
Passion: we are a multidisciplinary team of professionals passionate about scientific research and the application of science for social welfare.
-
Commitment: we believe in science at the service of the common good, focused on raising the quality of life and promoting a healthy future.
Our Technology
​The COVID-19 pandemic revealed the need for rapid, affordable solutions to diagnose, prevent, and treat this emerging disease. PCR detection has proven to be very useful for diagnosis due to its sensitivity and specificity. This left us with an unvaluable number of PCR equipment and PCR trained personnel that now became idle. This is a great opportunity to foster the development of new PCR kits that will exploit this idle infrastructure.
​
The Pandemic also has taught us that we need to be ready with new vaccine technologies. The mRNA and viral vector technologies have shown efficacy. However, these vaccine technologies also face challenges like inflammation, immune responses, regulatory complexity, and cold chain dependency.
To address these issues, we developed a proprietary plasmid DNA platform focused on creating accessible, cost-effective, and thermostable solutions with global impact that can be used not only for diagnostics and DNA vaccines, but also for recombinant protein production and Gene Therapy.
​
At Amplicon Bricks, our name embodies our core technology. We harness the precision of PCR amplification to isolate hundreds of genes—whether in their entirety or as essential fragments—and transform them into the fundamental "bricks" of our innovation. These amplicons are meticulously integrated into our proprietary plasmid DNA, establishing a modular platform that fuels breakthrough solutions in diagnostics, recombinant protein production, DNA vaccines, and gene therapies. By converting carefully amplified gene segments into versatile building blocks, we create a dynamic system where each brick contributes to a larger structure of advanced molecular tools. In essence, every amplicon brick we engineer is a step toward building a healthier, more sustainable future.
Our Products (B2C)
PCR Kits
​
We have completed the development of our first molecular detection PCR kits, which are now entering the QC and optimization phase and will be available soon.
Meanwhile, we continue developing additional PCR kits to expand our offerings.
Our goal is to make molecular detection accessible to everyone. If you have a specific need for PCR kits, let us know!
Interested in a free sample? Reach out to us.
​
Available Soon – November 2025!
Our Services (B2B)
Research Boutique
​
Our research boutique has engineered a proprietary non-viral plasmid platform optimized for the development and scalable production of recombinant proteins, gene therapies, and novel vaccines. We offer on-demand development services, allowing our clients to customize and create innovative solutions tailored to their specific needs. In addition, we continuously develop proprietary technologies, which we package as intellectual property-driven solutions, available for licensing or direct implementation.
​
We are currenlty working in the following projects:
-
Gene Therapy: GNAO1
-
Vaccines: Foot and mouth Disease
-
Recombinant Proteins: Epsilon Toxin Clostridium perfringens
​​
Here are our future steps in Gene Therapy, Veterinary and Human Vaccines.
Award Winners
In 2024, just six months after our founding, we were honored with the NAVES USA 2024 International Competition award, winning in the “Business Idea” category. This recognition strengthened our conviction and motivated us to keep advancing toward a promising future for our company—driven, above all, by our mission to put science at the service of the common good.
Meet The Team
With over 30 years of leadership in the agrobiotechnology sector, Jorge brings a unique blend of scientific expertise and strategic vision to his role as CEO. A Veterinary Doctor (DVM) with master’s degrees in Science, Technology & Innovation (MGCTI) and in Leadership & Sustainable Development (MDL), Jorge has held key positions including Director of INTA’s Agroindustry Research Center.
​
At Amplicon Bricks, he drives the company’s growth strategy and leads investor relations. He fosters cross-functional alignment to ensure sustainable execution and scalability, empowering teams to deliver impactful, long-term results.
​
Renowned for his visionary leadership, interdisciplinary thinking, and commitment to sustainable innovation, Jorge is dedicated to shaping a future where biotechnology delivers inclusive and transformative solutions.
Jorge E. Carrillo
Chief Executive Officer (CEO)
With over 15 years of experience at the forefront of biotechnology, Ana Clara has earned recognition as a leading expert in vaccine development and diagnostic innovation. A driving force behind pivotal projects, Ana Clara has successfully collaborated with private industry partners to develop vaccines for Foot-and-Mouth Disease Virus (FMDV) and COVID-19. Their extensive contributions include numerous scientific publications and an inventor’s patent, reflecting a deep commitment to advancing the field.
Ana Clara channels a wealth of expertise in molecular biology and synthetic biology to pioneer cutting-edge solutions. Renowned for strategic problem-solving, critical thinking, and precision, they excel in fostering impactful partnerships through exceptional communication and a collaborative mindset.
Dedicated to staying ahead of scientific breakthroughs, Ana Clara is unwavering in their mission to shape the future of biotechnology with innovation and purpose.
Ana Clara Mignaqui
Founder & Chief Scientific Officer
With extensive experience in diverse roles across Argentina and Latin America's pharmaceutical industry, Eduardo has developed a profound understanding of the sector. His strategic vision and natural, knowledge-driven leadership have been key to his success.
​
A medical doctor specializing in infectious diseases, Eduardo also holds a postgraduate degree in Pharmaceutical Medicine and serves as a lecturer in Pharmaceutical Marketing and Pharmacoeconomics.
​
His passion for research and translational medicine aligns seamlessly with Amplicon Bricks' mission, reflecting a shared commitment to advancing knowledge and bringing the latest healthcare innovations to people.
Eduardo de la Puente
Chief Medical Officer
An expert in strategic and corporate communications, Cecilia has dedicated over 15 years to working with leading national and international organizations across diverse industries in both the public and private sectors, as well as with civil society organizations.
Driven by a passion for health, Cecilia specializes in Public Health and Health Management. She led the Public Communication Department at Argentina’s Ministry of Health, served as an Associate Professor in Public Health at the University of El Salvador in Argentina (School of Medicine), and is an alumna of the U.S. Department of State's International Visitor Leadership Program (IVLP) in Global Health Leadership.
Her belief in the transformative power of communication to build healthier and more sustainable realities aligns perfectly with Amplicon Bricks' purpose of advancing a healthier future.
Cecilia Cragnaz
Chief Communications Officer
Advisory Board Members
Marcelo Grabois
Intellectual Property & Innovation
Florencia Paolini
Economy and Finance
Samuel Kreiman
Legal Affairs
Ricardo Beller
Legal Affairs
Silvia Torres Carbonell
Entrepreneurship
Maribel García
Accountant
Juan Sebastián Pappalardo
Vaccine Development
We recognize that achieving our goals is only possible through the efforts of a talented and dedicated team. The passion, expertise, and commitment of everyone at Amplicon Bricks are our greatest assets.
Our exceptional team brings together experts in biotechnology, synthetic biology, pharmaceutical medicine, intellectual property, communication, and marketing.
Contact Us
If you have any specific needs in molecular detection by PCR or are interested in developing novel vaccines, gene therapies, or recombinant proteins using our DNA platform, don’t hesitate to reach out!
We’re here to help.
​
